A study on whether fasting glucagon values affect the effect of DPP4 inhibitors on type 2 diabetic patients.
- Conditions
- Type 2 diabetes (insulin independent diabetes )
- Registration Number
- JPRN-UMIN000030698
- Lead Sponsor
- Kitasato University
- Brief Summary
This study was discontinued.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2
Not provided
1. Cases of contraindications described in the package insert of sitagliptin 2. Cases during administration of DPP-4 inhibitor containing sitagliptin. 3. Cases during GLP-1 receptor agonist administration. 4. Patients treated with insulin (also switching to DPP-4 inhibitors) 5. Treating acute diseases. 6. Cases of malignant tumor complication and its history. 7. A case with moderate or higher renal dysfunction (Japanese estimated creatinine clearance <50 ml/min). 8. Liver function disorder associated with either AST (GOT) >100 IU/dl or ALT (GPT) >100 IU/dl 9. Pregnant women or women who may be pregnant. 10. A lactating woman. 11. A Case difficult to confirm whose intention. 12. Cases of complication of endocrine disorder. 13. A cases who uses drugs known to have side effects causing glucose metabolism (steroid drugs,Interferon etc) . 14. History of abdominal surgery. 15. Patients with metabolic incontinence symptoms associated with diabetes such as dry mouth, polydipsia, polyuria, nocturnal urine, and weight loss. 16. Cases with geriatric syndrome (sarcopenia, cognitive decline, ADL lowering etc).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Verification of difference in blood glucose improving effect of DPP-4 inhibitor in cases of type 2 diabetes with high or low fasting glucagon value.
- Secondary Outcome Measures
Name Time Method